Collaboration
propels innovation

arrow

Collaboration
propels innovation

arrow

Who we are

Ichnos Glenmark Innovation, an alliance between Ichnos Sciences and Glenmark Pharma, combines internal and external forces to create cutting-edge therapy solutions. Solutions that treat hematological malignancies and solid tumors and bring new hope for patients, their families and healthcare professionals alike.

At a glance

Robust pipeline

isb1442

isb2001

isb1342

isb1442

isb1442

isb1442

Robust pipeline

Coming Soon……

Latest Updates

We are open for collaboration

For the latest updates, follow us on LinkedIn
Want to create something cutting edge with us? Join us.

Our Team - Cyril_Konto

Cyril Konto, M.D.

President and Chief Executive Officer
Ichnos Glenmark Innovation

Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.

At Pfizer, he was Executive Director of Early Immuno-oncology Clinical  Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.

Cyril Konto, M.D.
Our Team - Cyril_Konto

Cyril Konto, M.D.

President and Chief Executive Officer
Ichnos Glenmark Innovation

Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.

At Pfizer, he was Executive Director of Early Immuno-oncology Clinical  Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.

President and Chief Executive Officer
Our Team - Cyril_Konto

Cyril Konto, M.D.

President and Chief Executive Officer
Ichnos Glenmark Innovation

Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.

At Pfizer, he was Executive Director of Early Immuno-oncology Clinical  Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.

Our Team - Cyril_Konto

Cyril Konto, M.D.

President and Chief Executive Officer
Ichnos Glenmark Innovation

Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.

At Pfizer, he was Executive Director of Early Immuno-oncology Clinical  Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.

Cyril Konto, M.D.
Our Team - Cyril_Konto

Cyril Konto, M.D.

President and Chief Executive Officer
Ichnos Glenmark Innovation

Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.

At Pfizer, he was Executive Director of Early Immuno-oncology Clinical  Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.

President and Chief Executive Officer
Our Team - Cyril_Konto

Cyril Konto, M.D.

President and Chief Executive Officer
Ichnos Glenmark Innovation

Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.

At Pfizer, he was Executive Director of Early Immuno-oncology Clinical  Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.

Our Team - Cyril_Konto

Cyril Konto, M.D.

President and Chief Executive Officer
Ichnos Glenmark Innovation

Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.

At Pfizer, he was Executive Director of Early Immuno-oncology Clinical  Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.

Cyril Konto, M.D.
Our Team - Cyril_Konto

Cyril Konto, M.D.

President and Chief Executive Officer
Ichnos Glenmark Innovation

Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.

At Pfizer, he was Executive Director of Early Immuno-oncology Clinical  Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.

President and Chief Executive Officer
Our Team - Cyril_Konto

Cyril Konto, M.D.

President and Chief Executive Officer
Ichnos Glenmark Innovation

Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.

At Pfizer, he was Executive Director of Early Immuno-oncology Clinical  Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.

Our Team - Cyril_Konto

Cyril Konto, M.D.

President and Chief Executive Officer
Ichnos Glenmark Innovation

Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.

At Pfizer, he was Executive Director of Early Immuno-oncology Clinical  Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.

Cyril Konto, M.D.
Our Team - Cyril_Konto

Cyril Konto, M.D.

President and Chief Executive Officer
Ichnos Glenmark Innovation

Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.

At Pfizer, he was Executive Director of Early Immuno-oncology Clinical  Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.

President and Chief Executive Officer
Our Team - Cyril_Konto

Cyril Konto, M.D.

President and Chief Executive Officer
Ichnos Glenmark Innovation

Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.

At Pfizer, he was Executive Director of Early Immuno-oncology Clinical  Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.

Cyril Konto, M.D.
Our Team - Cyril_Konto

Cyril Konto, M.D.

President and Chief Executive Officer
Ichnos Glenmark Innovation

Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.

At Pfizer, he was Executive Director of Early Immuno-oncology Clinical  Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.

President and Chief Executive Officer
Our Team - Cyril_Konto

Cyril Konto, M.D.

President and Chief Executive Officer
Ichnos Glenmark Innovation

Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.

At Pfizer, he was Executive Director of Early Immuno-oncology Clinical  Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.

Cyril Konto, M.D.
Our Team - Cyril_Konto

Cyril Konto, M.D.

President and Chief Executive Officer
Ichnos Glenmark Innovation

Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.

At Pfizer, he was Executive Director of Early Immuno-oncology Clinical  Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.

President and Chief Executive Officer
Our Team - Cyril_Konto

Cyril Konto, M.D.

President and Chief Executive Officer
Ichnos Glenmark Innovation

Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.

At Pfizer, he was Executive Director of Early Immuno-oncology Clinical  Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.

Cyril Konto, M.D.
Our Team - Cyril_Konto

Cyril Konto, M.D.

President and Chief Executive Officer
Ichnos Glenmark Innovation

Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.

At Pfizer, he was Executive Director of Early Immuno-oncology Clinical  Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.

President and Chief Executive Officer
Our Team - Cyril_Konto

Cyril Konto, M.D.

President and Chief Executive Officer
Ichnos Glenmark Innovation

Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.

At Pfizer, he was Executive Director of Early Immuno-oncology Clinical  Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.

Cyril Konto, M.D.
Our Team - Cyril_Konto

Cyril Konto, M.D.

President and Chief Executive Officer
Ichnos Glenmark Innovation

Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.

At Pfizer, he was Executive Director of Early Immuno-oncology Clinical  Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.

President and Chief Executive Officer
Our Team - Cyril_Konto

Cyril Konto, M.D.

President and Chief Executive Officer
Ichnos Glenmark Innovation

Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.

At Pfizer, he was Executive Director of Early Immuno-oncology Clinical  Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.

Primary Logo Desktop2